143 related articles for article (PubMed ID: 12670552)
1. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder.
Guan KP; Ye HY; Yan Z; Wang Y; Hou SK
Urology; 2003 Apr; 61(4):719-23. PubMed ID: 12670552
[TBL] [Abstract][Full Text] [Related]
2. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
3. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.
Davies B; Waxman J; Wasan H; Abel P; Williams G; Krausz T; Neal D; Thomas D; Hanby A; Balkwill F
Cancer Res; 1993 Nov; 53(22):5365-9. PubMed ID: 8221672
[TBL] [Abstract][Full Text] [Related]
4. [Detection of serum levels of MMP-9 and VEGF in patients with bladder cancer].
Guan KP; Hou SK; Yan Z; Ye HY
Zhonghua Wai Ke Za Zhi; 2003 Jun; 41(6):430-2. PubMed ID: 12895351
[TBL] [Abstract][Full Text] [Related]
5. Expression of matrix metalloproteinases in human transitional cell carcinoma of the urinary bladder.
Sumi T; Yoshida H; Hyun Y; Yasui T; Matsumoto Y; Hattori K; Sugimura K; Kawashima H; Nakatani T; Ishiko O
Oncol Rep; 2003; 10(2):345-9. PubMed ID: 12579270
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
7. Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer.
Szarvas T; László V; Vom Dorp F; Reis H; Szendröi A; Romics I; Tilki D; Rübben H; Ergün S
Int J Cancer; 2012 Jun; 130(12):2922-9. PubMed ID: 21815140
[TBL] [Abstract][Full Text] [Related]
8. Preoperative levels of matrix metalloproteinase-7 and -9 and tissue inhibitor of matrix metalloproteinase-1 relation to pathologic parameters in bladder carcinoma patients.
Gunes M; Kemik AS; Pirincci N; Gecit I; Taken K; Yuksel MB; Kaba M; Eryilmaz R
Asian Pac J Cancer Prev; 2013; 14(2):873-6. PubMed ID: 23621254
[TBL] [Abstract][Full Text] [Related]
9. The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer.
Ramón de Fata F; Ferruelo A; Andrés G; Gimbernat H; Sánchez-Chapado M; Angulo JC
Actas Urol Esp; 2013 Sep; 37(8):480-8. PubMed ID: 23916137
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer.
Vasala K; Pääkkö P; Turpeenniemi-Hujanen T
Urology; 2003 Nov; 62(5):952-7. PubMed ID: 14624933
[TBL] [Abstract][Full Text] [Related]
11. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
Feldman AL; Tamarkin L; Paciotti GF; Simpson BW; Linehan WM; Yang JC; Fogler WE; Turner EM; Alexander HR; Libutti SK
Clin Cancer Res; 2000 Dec; 6(12):4628-34. PubMed ID: 11156212
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder.
Candido S; Di Maso M; Serraino D; McCubrey JA; Bortolus R; Zanin M; Battiston M; Salemi R; Libra M; Polesel J
Tumour Biol; 2016 Jul; 37(7):9855-63. PubMed ID: 26810191
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis.
Vasala K; Pääkko P; Turpeenniemi-Hujanen T
Anticancer Res; 2008; 28(3B):1757-61. PubMed ID: 18630455
[TBL] [Abstract][Full Text] [Related]
14. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer.
Suzuki M; Iizasa T; Ko E; Baba M; Saitoh Y; Shibuya K; Sekine Y; Yoshida S; Hiroshima K; Fujisawa T
Lung Cancer; 2002 Jan; 35(1):29-34. PubMed ID: 11750710
[TBL] [Abstract][Full Text] [Related]
15. Serum endostatin levels in patients with epithelial ovarian cancer.
Hata K; Dhar DK; Kanasaki H; Nakayama K; Fujiwaki R; Katabuchi H; Okamura H; Nagasue N; Miyazaki K
Anticancer Res; 2003; 23(2C):1907-12. PubMed ID: 12820477
[TBL] [Abstract][Full Text] [Related]
16. The role of serum laminin P1 in the diagnosis of transitional cell carcinoma of the bladder.
Abou Farha KM; Menheere PP; Bruins JL; Kester AD; Janknegt R
Eur Urol; 1992; 21(3):240-4. PubMed ID: 1499633
[TBL] [Abstract][Full Text] [Related]
17. Relation between basement membrane degradation and serum levels of laminin P1 in patients with transitional cell carcinoma of the bladder.
Abou Farha KM; Menheere PP; Nieman FH; Janknegt RA; Arends JW
Urol Int; 1993; 50(1):13-6. PubMed ID: 8434420
[TBL] [Abstract][Full Text] [Related]
18. Significance of serum laminin P1 values in patients with transitional cell carcinoma of the bladder.
Mungan U; Kirkali G; Celebi I; Kirkali Z
Urology; 1996 Sep; 48(3):496-500. PubMed ID: 8804512
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
[TBL] [Abstract][Full Text] [Related]
20. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.
Staack A; Badendieck S; Schnorr D; Loening SA; Jung K
BMC Urol; 2006 Aug; 6():19. PubMed ID: 16901349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
